Clinical Trial ResultsBiomea's 52-week Ph2 COVALENT-111 data are strong, showing continuation of HbA1c benefit well beyond cessation of icovamenib, positioning icovamenib as a potential alternative to existing chronic treatments for T2D.
Potential In Combination TherapyIcovamenib, in combination with semaglutide, demonstrated superior metabolic benefits in rodent models compared to semaglutide alone, highlighting its potential efficacy.